British journal of pharmacology · 2014 · Review · PMID 24117165
Explore the library
Limited human evidenceElamipretide; mitochondria-targeted tetrapeptide
SS-31 / Elamipretide
SS-31 is a research name for elamipretide, a mitochondria-targeted tetrapeptide. The finished product Forzinity has a narrow accelerated FDA approval for Barth syndrome, not healthy-person longevity.
Also indexed as: Elamipretide · MTP-131
A clear starting point
SS-31 is a research name for elamipretide, a mitochondria-targeted tetrapeptide. The finished product Forzinity has a narrow accelerated FDA approval for Barth syndrome, not healthy-person longevity.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Cardiolipin / mitochondrial membrane
SS-31 is a research name for elamipretide, a mitochondria-targeted tetrapeptide. The finished product Forzinity has a narrow accelerated FDA approval for Barth syndrome, not healthy-person longevity.
- Targets & processes
- Cardiolipin / mitochondrial membrane
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Mitochondrial membrane function and disease-specific outcomes.
What this does not establish
Forzinity received accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. A confirmatory trial is required. This is not evidence for healthy-person longevity.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Injection-site reactions are common in trials; serious hypersensitivity reactions have been reported. Refer to the approved product label for full contraindications and warnings.
Contraindications & cautions
Not an exhaustive contraindication review. Injection-site reactions are common in trials; serious hypersensitivity reactions have been reported. Refer to the approved product label for full contraindications and warnings.
Medication & supplement interactions
Interaction information is incomplete. Injection-site reactions are common in trials; serious hypersensitivity reactions have been reported. Refer to the approved product label for full contraindications and warnings.
Regulatory status · United States
FDA accelerated approval · Barth syndrome. Forzinity (elamipretide) received accelerated FDA approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Confirmatory evidence is required. This does not approve longevity use or research-grade SS-31.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.